Literature DB >> 894796

Malignant pheochromocytoma: clinical course and treatment.

E M Mahoney, J H Harrison.   

Abstract

We describe 7 patients with 16 malignant pheochromocytomas, with followup for 7 to 21 years. Five patients are free of disease at a mean of 13.5 years and 2 patients died of malignancy at 10 and 13 years. The 3 criteria believed important for a maximum tumor-free interval are: 1) adjunctive lymphadenectomy at the initial operation when 1 or more lymph nodes contain tumor, 2) close followup of all patients with pheochromocytoma by diagnostic biochemical assay for 15 years and 3) an aggressive excision of all single or multiple recurrent pheochromocytomas as soon as a biochemical diagnosis is established.

Entities:  

Mesh:

Year:  1977        PMID: 894796     DOI: 10.1016/s0022-5347(17)57951-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Hypertension in patients with pheochromocytoma.

Authors:  N N Hanna; D E Kenady
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369

2.  CT localization of occult secretory tumors in children.

Authors:  S T Hecht; R C Brasch; D M Styne
Journal:  Pediatr Radiol       Date:  1982

3.  Persistent and recurrent pheochromocytoma: the role of surgery.

Authors:  M F Brennan; H R Keiser
Journal:  World J Surg       Date:  1982-07       Impact factor: 3.352

Review 4.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

Review 5.  A case of pheochromocytoma with severe paralytic ileus.

Authors:  M Noguchi; T Taniya; K Ueno; M Yagi; R Izumi; K Konishi; I Miyazaki
Journal:  Jpn J Surg       Date:  1990-07

Review 6.  The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.

Authors:  K C Loh; P A Fitzgerald; K K Matthay; P P Yeo; D C Price
Journal:  J Endocrinol Invest       Date:  1997-12       Impact factor: 4.256

7.  Radionuclide therapy of malignant pheochromocytoma with 131I-MIBG.

Authors:  Y Nakabeppu; M Nakajo
Journal:  Ann Nucl Med       Date:  1994-11       Impact factor: 2.668

8.  Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases.

Authors:  M Schlumberger; C Gicquel; J Lumbroso; F Tenenbaum; E Comoy; J Bosq; E Fonseca; P P Ghillani; B Aubert; J P Travagli
Journal:  J Endocrinol Invest       Date:  1992-10       Impact factor: 4.256

9.  Pheochromocytoma presenting as musculoskeletal pain from bone metastases.

Authors:  M D Lynn; E M Braunstein; B Shapiro
Journal:  Skeletal Radiol       Date:  1987       Impact factor: 2.199

10.  Multiple venous sampling for catecholamine assay in the diagnosis of malignant pheochromocytoma.

Authors:  R Pontremoli; G Borgonovo; A Ranise; G Garibotto
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.